<DOC>
	<DOC>NCT02577094</DOC>
	<brief_summary>Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.</brief_summary>
	<brief_title>Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>- Physical examination (screening and follow-up) - Complete blood counts (screening and follow-up) - Dosage of FLT3-ligand in plasma (screening and follow-up) - Blood ionogramme, creatinine hepatic work-up (screening and follow-up) - Left ventricular ejection fraction at pre-implant assessment - Immunization test (screening and follow-up) - Bone marrow aspiration or/and blood CD 22 immunophenotype for minimal residual disease evaluation (screening and follow-up) - All exams which were initially abnormal and which are necessary for response evaluation and All exams which are needed in case of relapse suspicion. - Pharmacokinetic of 90Y-hLL2</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age ≥ 18 Acute lymphoblastic Leukemia (ALL) CD22 + Btype in RC1 with high risk BCell Acute Lymphoblastic Leukemia (ALL) CD22+ beyond RC1. Expression of CD22 ≥ 30% in tumor population evaluated by flow cytometry or immunohistochemistry at diagnosis stage or relapse stage. HLAidentical donor intra family or not, without major HLA mismatch (9 / 10th accepted) without contraindication for stem cell mobilization ECOG (Eastern Cooperative Oncology Group) ≤ 2 Having or not received previously Epratuzumab Eligible for an allograft with reduced conditioning regimen With a signed informed consent Patient in age of children bearing with adequate contraception Patient affiliated to or beneficiary of the National Health Service Tcell ALL Known hypersensibility to 90YDOTAhLL2 Immunization against hLL2 for patients having already received one or several injections of this antibody Patient eligible for myeloablative conditioning regimen Other prior malignancies must have had at least a 2year diseasefree interval with the exception of successfully treated carcinoma skin cancer or carcinoma in situ of the cervix. Patient with progressive psychiatric condition. HIV positive, hepatitis Bantigen positive, or hepatitis C positive patients who need a treatment Pregnant or breastfeeding women Women with childbearing potential without effective contraception Serious concomitant and uncontrolled infection Usual contraindications in the allogeneic transplant: Adult patient protected by the French law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CD22 positive- lymphoblastic leukemia-RIT-Yttrium</keyword>
</DOC>